Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 29Other hematologic neoplasm 19CNS 14Thoracic 7Breast 6Myeloid 3Dermatologic 2Sarcoma 1Plasma cell 1

Conditions

Uveal Melanoma 1Nevus 1Meningeal Neoplasms 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 193aldesleukin 145Interleukin-2 109fludarabine phosphate 106Temozolomide 83Dacarbazine 81fludarabine 80Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Carboplatin 48Magnetic Resonance Spectroscopy 47Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42atezolizumab 41Specimen Handling 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Spinal Puncture × Dermatologic × Clear all
NCT03025256 2026-05-05

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

M.D. Anderson Cancer Center

Phase 1 Recruiting
75 enrolled
DermatologicThoracic

Uveal Melanoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Meningeal Neoplasms, Nevus

NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 24 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡